drugset / Trial / NCT07288749

Summary

Evaluating the safety and efficacy of glimepiride in patients with type 2 diabetes and chronic heart failure with reduced ejection fraction--a multicenter randomized controlled study.

Timeline

Start
2026-01-01
Primary completion
2030-12-31
Completion
2031-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Glimepiride Small molecule 2 mg Oral
Subject Glimepiride Small molecule 4 mg Oral